FR2966366B1 - Composition de gel de brimonidine - Google Patents

Composition de gel de brimonidine

Info

Publication number
FR2966366B1
FR2966366B1 FR1058612A FR1058612A FR2966366B1 FR 2966366 B1 FR2966366 B1 FR 2966366B1 FR 1058612 A FR1058612 A FR 1058612A FR 1058612 A FR1058612 A FR 1058612A FR 2966366 B1 FR2966366 B1 FR 2966366B1
Authority
FR
France
Prior art keywords
gel composition
brimonidine gel
brimonidine
composition
gel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1058612A
Other languages
English (en)
Other versions
FR2966366A1 (fr
Inventor
Jean Christophe Buge
Fourcade Karine Nadau
Cyril Meunier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma SA
Original Assignee
Galderma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1058612A priority Critical patent/FR2966366B1/fr
Application filed by Galderma SA filed Critical Galderma SA
Priority to ARP110103864A priority patent/AR083651A1/es
Priority to AU2011317554A priority patent/AU2011317554B2/en
Priority to RU2013123042/15A priority patent/RU2571277C2/ru
Priority to PT111858106T priority patent/PT2444068E/pt
Priority to DK11185810.6T priority patent/DK2444068T4/en
Priority to NO11185810A priority patent/NO2444068T3/no
Priority to RSP20140468 priority patent/RS53531B1/en
Priority to CA2814952A priority patent/CA2814952C/fr
Priority to PCT/EP2011/068263 priority patent/WO2012052479A2/fr
Priority to EP11185810.6A priority patent/EP2444068B2/fr
Priority to NZ610121A priority patent/NZ610121A/en
Priority to US13/824,635 priority patent/US20130261126A1/en
Priority to BR112013009578-4A priority patent/BR112013009578B1/pt
Priority to EP11805792.6A priority patent/EP2629757A2/fr
Priority to MX2013004473A priority patent/MX354697B/es
Priority to SI201130261T priority patent/SI2444068T1/sl
Priority to CN201180050899.2A priority patent/CN103298451B/zh
Priority to JP2013534309A priority patent/JP2013540143A/ja
Priority to KR1020137012870A priority patent/KR101506102B1/ko
Priority to SG2013028147A priority patent/SG189896A1/en
Priority to ES11185810.6T priority patent/ES2498217T5/es
Priority to PL11185810T priority patent/PL2444068T5/pl
Publication of FR2966366A1 publication Critical patent/FR2966366A1/fr
Application granted granted Critical
Publication of FR2966366B1 publication Critical patent/FR2966366B1/fr
Priority to IL225760A priority patent/IL225760A/en
Priority to ZA2013/02859A priority patent/ZA201302859B/en
Priority to ZA2014/02758A priority patent/ZA201402758B/en
Priority to HRP20140811AT priority patent/HRP20140811T1/hr
Priority to CY20141100705T priority patent/CY1115683T1/el
Priority to SM201400156T priority patent/SMT201400156B/xx
Priority to JP2015207802A priority patent/JP6185536B2/ja
Priority to US15/220,501 priority patent/US10201517B2/en
Priority to IL251543A priority patent/IL251543B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
FR1058612A 2010-10-21 2010-10-21 Composition de gel de brimonidine Expired - Fee Related FR2966366B1 (fr)

Priority Applications (32)

Application Number Priority Date Filing Date Title
FR1058612A FR2966366B1 (fr) 2010-10-21 2010-10-21 Composition de gel de brimonidine
KR1020137012870A KR101506102B1 (ko) 2010-10-21 2011-10-19 브리모니딘 겔 조성물 및 사용 방법
CN201180050899.2A CN103298451B (zh) 2010-10-21 2011-10-19 溴莫尼定凝胶剂组合物及其使用方法
AU2011317554A AU2011317554B2 (en) 2010-10-21 2011-10-19 Brimonidine gel compositions and methods of use
DK11185810.6T DK2444068T4 (en) 2010-10-21 2011-10-19 Brimonide sub-composition
NO11185810A NO2444068T3 (fr) 2010-10-21 2011-10-19
RSP20140468 RS53531B1 (en) 2010-10-21 2011-10-19 BRIMONIDINE GEL COMPOSITION
CA2814952A CA2814952C (fr) 2010-10-21 2011-10-19 Compositions de gel de brimonidine et leurs procedes d'utilisation
PCT/EP2011/068263 WO2012052479A2 (fr) 2010-10-21 2011-10-19 Compositions de gel de brimonidine et leurs procédés d'utilisation
EP11185810.6A EP2444068B2 (fr) 2010-10-21 2011-10-19 Composition de gel de brimonidine
NZ610121A NZ610121A (en) 2010-10-21 2011-10-19 Brimonidine gel compositions and methods of use
US13/824,635 US20130261126A1 (en) 2010-10-21 2011-10-19 Brimonidiine gel compositions and methods of use
BR112013009578-4A BR112013009578B1 (pt) 2010-10-21 2011-10-19 composição tópica em gel e uso de uma composição tópica em gel
EP11805792.6A EP2629757A2 (fr) 2010-10-21 2011-10-19 Compositions de gel de brimonidine et leurs procédés d'utilisation
MX2013004473A MX354697B (es) 2010-10-21 2011-10-19 Composiciones de gel de brimonidina y métodos de uso.
SI201130261T SI2444068T1 (sl) 2010-10-21 2011-10-19 Brimodin gel sestavek
ARP110103864A AR083651A1 (es) 2010-10-21 2011-10-19 Composiciones de brimonidina en gel y metodos de uso
PT111858106T PT2444068E (pt) 2010-10-21 2011-10-19 Composição de gel de brimonidina
JP2013534309A JP2013540143A (ja) 2010-10-21 2011-10-19 ブリモニジンゲル組成物及び使用方法
SG2013028147A SG189896A1 (en) 2010-10-21 2011-10-19 Brimonidine gel compositions and methods of use
ES11185810.6T ES2498217T5 (es) 2010-10-21 2011-10-19 Composición en forma de gel basada en brimonidina
PL11185810T PL2444068T5 (pl) 2010-10-21 2011-10-19 Kompozycja żelowa z brymonidyną
RU2013123042/15A RU2571277C2 (ru) 2010-10-21 2011-10-19 Композиции геля с бримонидином и способы применения
IL225760A IL225760A (en) 2010-10-21 2013-04-15 Brimonide gel preparations
ZA2013/02859A ZA201302859B (en) 2010-10-21 2013-04-19 Brimonidine gel compositions and methods of use
ZA2014/02758A ZA201402758B (en) 2010-10-21 2014-04-15 Brimonidine gel compositions and methods of use
HRP20140811AT HRP20140811T1 (hr) 2010-10-21 2014-08-27 Kompozicija brimonidin gela
CY20141100705T CY1115683T1 (el) 2010-10-21 2014-09-03 Συνθεση ζελε brimonidine
SM201400156T SMT201400156B (it) 2010-10-21 2014-10-27 Composizione di gel di brimonidina
JP2015207802A JP6185536B2 (ja) 2010-10-21 2015-10-22 ブリモニジンゲル組成物及び使用方法
US15/220,501 US10201517B2 (en) 2010-10-21 2016-07-27 Brimonidine gel compositions and methods of use
IL251543A IL251543B (en) 2010-10-21 2017-04-03 Use of gel compounds in the production of medicine to prevent or treat skin diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1058612A FR2966366B1 (fr) 2010-10-21 2010-10-21 Composition de gel de brimonidine

Publications (2)

Publication Number Publication Date
FR2966366A1 FR2966366A1 (fr) 2012-04-27
FR2966366B1 true FR2966366B1 (fr) 2012-11-09

Family

ID=43757824

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1058612A Expired - Fee Related FR2966366B1 (fr) 2010-10-21 2010-10-21 Composition de gel de brimonidine

Country Status (1)

Country Link
FR (1) FR2966366B1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20090061020A1 (en) * 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
JP5580210B2 (ja) * 2007-12-21 2014-08-27 ガルデマ ラボラトリーズ インコーポレイテッド 手術前治療

Also Published As

Publication number Publication date
FR2966366A1 (fr) 2012-04-27

Similar Documents

Publication Publication Date Title
SMT201700008B (it) Composizione farmaceutica
BR112013011472A2 (pt) Composição de gel
SMT201500054B (it) 2-Anilinobenzimidazolo-6-carbossammidi come agentianti-infiammattori
BR112013016037A2 (pt) composição em gel.
BR112012031667A2 (pt) composição
DK2640893T4 (da) Sammensætninger
DK3257890T3 (da) Tværbindelig sammensætning
BR112012028549A2 (pt) escova de dentes
BR112012028556A2 (pt) Indóis
BR112012032683A2 (pt) composição
BR112013014989A2 (pt) completamento de poço
DK3246018T3 (da) Farmaceutisk sammensætning
IT1400743B1 (it) Composizioni polimeriche
BR112013011850A2 (pt) escova de dentes
SMT201400156B (it) Composizione di gel di brimonidina
DK3095817T3 (da) Mikrogelsammensætninger
EE201300005A (et) Ravimkoostis
FR2955770B1 (fr) Composition cosmetique.
BR112012027261A2 (pt) composição de shampoo condicionador
BR112012032980A2 (pt) composição
FR2958537B1 (fr) Composition dentaire
BR112012028007A2 (pt) composição aquosa
FR2957252B1 (fr) Composition cosmetique
FR2957787B1 (fr) Composition de maquillage
BR112012029461A2 (pt) composição farmacêutica contendo solifenacina

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

ST Notification of lapse

Effective date: 20201005